AGMB
Agomab Therapeutics NV
$13.28
-0.24 (-1.78%)
At close · Jul 7
Market Cap
$654.01M
Shares
49,247,975
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.28
Open$13.63
Day$12.50–13.95
52W$8.75–17.82
Avg vol 30d110K
Short int1.1M · 2.2% float · 9.2d
Short vol53%
DataFeb 2026–Jul 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Buy
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+15%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
50%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
1 of 32 funds reported for Jun 30 · net +1.3K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.17% of float · ▲ +35.2% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
32 holders — 13F breadth
Squeeze score
71
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
99%
annualized · 1-yr
Max drawdown
−41%
past year
ATR
12.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+15%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
50%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
1 of 32 funds reported for Jun 30 · net +1.3K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.17% of float · ▲ +35.2% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
32 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $9
Now $13 · 50%
52-wk high $18
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AGMB
this stock
Agomab Therapeutics NV
|
$654.01M | — | — | — | 2.2% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AGMB | -25.5% | +33.9% | — | +2.3% | — |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -26.4% | +32.5% | — | +2.2% | — |